Project Grant W81XWH2010874

This $367,577 Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) to Adepthera LLC aims to develop a regenerative peptide therapy to accelerate pressure ulcer healing. Specifically, the award will fund research to identify an optimal formulation of a self-assembling adrenomedullin (ADM) analog gel that can improve local blood circulation and wound healing in aging and diabetic mouse models. The proposed therapy would be administered weekly or biweekly via...

This Project Grant award, made by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports the development of Dermisphere, an advanced dermal regeneration scaffold product by Fesariustherapeutics Inc. The $349,345 award aims to demonstrate the feasibility of using Dermisphere to manage acute major burn wounds. Preliminary studies have shown that Dermisphere can support rapid and sustained cellular...

This Cooperative Agreement award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $536,233 to Northwestern University to develop a synthetic melanin-based treatment to accelerate wound healing and reduce scarring resulting from exposure to mustard gas. The project aims to evaluate a group of synthetic melanin particles (SMPs) for their ability to mitigate initial skin injury and promote faster wound repair...

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Gelsana Therapeutics Inc. a $649,984 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop Provasliex Gel, a zwitterionic hydrogel that delivers controlled release of platelet-derived growth factor (PDGF). The goal is to improve wound healing for diabetic foot ulcers by reducing inflammation, promoting vascularization, and accelerating the wound...

This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), is providing $208,125 to the University of Connecticut Health Center to develop an intralesional drug delivery strategy for treating infected wounds. The key products and services to be delivered include: Characterization of in situ formed microneedle-like drug depots and...

This federal Project Grant award, funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), aims to develop a novel therapeutic approach to improve angiogenesis and wound healing by delivering apoptotic neutrophils within a degradable hydrogel scaffold. The $172,700 award, effective August 20, 2024 through July 31, 2026, supports research to investigate the effects of the hydrogel-apoptotic neutrophil delivery on macrophage angiogenic signaling and its impact...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), is supporting research to understand the molecular mechanisms by which sex hormones, such as testosterone and estradiol, modulate wound healing. The $884,888 award, effective September 17, 2024 through March 12, 2025, aims to define how testosterone impairs wound healing through effects on the immune response, and how estradiol may...

This $252,906 National Science Foundation project grant supports the development of scalable manufacturing methods for peptide amphiphile molecules by Amphix Bio Inc. The goal is to advance a safer and more affordable alternative to recombinant proteins currently used in spinal fusion surgeries. Over 500,000 such surgeries are performed annually in the U.S. to treat back and neck pain. While peptide amphiphiles show promise for reducing biological dose needs and offering consistent outcomes,...

The National Institute on Aging (NIA) awarded a $295,923 Project Grant (CFDA 93.866 - Aging Research) to Larix Bioscience LLC to develop novel hormonal therapeutics and study their efficacy with adult stem cells for the treatment of chronic pressure ulcers. The project aims to generate stable, bioactive hormone fusion biologics and evaluate their ability to enhance tissue regeneration in pressure ulcer patients, both alone and in combination with adipose-derived or induced pluripotent stem...

This Project Grant award of $389,754 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to assess the therapeutic potential of a peptide derived from collagen XVIII for treating lung fibrosis associated with systemic sclerosis (scleroderma). The project aims to evaluate the anti-fibrotic effects of this peptide in a murine model of lung fibrosis, as well as identify the minimal effective dose, optimal...